188 related articles for article (PubMed ID: 3013992)
21. Antibodies to synthetic peptides from Epstein-Barr nuclear antigen-1 in sera of patients with early rheumatoid arthritis and in preillness sera.
Kouri T; Petersen J; Rhodes G; Aho K; Palosuo T; Heliövaara M; Isomäki H; von Essen R; Vaughan JH
J Rheumatol; 1990 Nov; 17(11):1442-9. PubMed ID: 2177109
[TBL] [Abstract][Full Text] [Related]
22. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus and rheumatoid arthritis.
Balandraud N; Roudier J; Roudier C
Autoimmun Rev; 2004 Jul; 3(5):362-7. PubMed ID: 15288002
[TBL] [Abstract][Full Text] [Related]
25. Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen.
Rhodes G; Carson DA; Valbracht J; Houghten R; Vaughan JH
J Immunol; 1985 Jan; 134(1):211-6. PubMed ID: 2981091
[TBL] [Abstract][Full Text] [Related]
26. Antibody responses to two Epstein-Barr virus nuclear antigens defined by gene transfer.
Miller G; Grogan E; Fischer DK; Niederman JC; Schooley RT; Henle W; Lenoir G; Liu CR
N Engl J Med; 1985 Mar; 312(12):750-5. PubMed ID: 2983211
[TBL] [Abstract][Full Text] [Related]
27. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis.
Ferrell PB; Aitcheson CT; Pearson GR; Tan EM
J Clin Invest; 1981 Mar; 67(3):681-7. PubMed ID: 6259207
[TBL] [Abstract][Full Text] [Related]
28. High titer of antibody to the Epstein-Barr virus membrane antigen in sera from patients with rheumatoid arthritis and systemic lupus erythematosus.
Yokochi T; Yanagawa A; Kimura Y; Mizushima Y
J Rheumatol; 1989 Aug; 16(8):1029-32. PubMed ID: 2555505
[TBL] [Abstract][Full Text] [Related]
29. Lack of relationship between the Epstein-Barr virus and the antiperinuclear factor/'perinuclear antigen' system in rheumatoid arthritis.
Buisson M; Berthelot JM; Le Goff P; Chastel C; Lamour A; Seigneurin JM; Youinou P
J Autoimmun; 1994 Aug; 7(4):485-95. PubMed ID: 7980850
[TBL] [Abstract][Full Text] [Related]
30. What is after cytokine-blocking therapy, a novel therapeutic target--synovial Epstein-Barr virus for rheumatoid arthritis.
Sawada S; Takei M; Inomata H; Nozaki T; Shiraiwa H
Autoimmun Rev; 2007 Jan; 6(3):126-30. PubMed ID: 17289546
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
O'Sullivan CE; Peng R; Cole KS; Montelaro RC; Sturgeon T; Jenson HB; Ling PD
J Med Virol; 2002 Jul; 67(3):320-6. PubMed ID: 12116021
[TBL] [Abstract][Full Text] [Related]
32. Antiperinuclear factor, a rheumatoid arthritis specific autoantibody: its relation to Epstein-Barr virus.
Westgeest AA; van Loon AM; van der Logt JT; van de Putte LB; Boerbooms AM
J Rheumatol; 1989 May; 16(5):626-30. PubMed ID: 2547060
[TBL] [Abstract][Full Text] [Related]
33. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA- and DNA-in situ hybridization.
Mehraein Y; Lennerz C; Ehlhardt S; Remberger K; Ojak A; Zang KD
Mod Pathol; 2004 Jul; 17(7):781-9. PubMed ID: 15044921
[TBL] [Abstract][Full Text] [Related]
34. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
35. Unchanged expression of Epstein-Barr virus-determined nuclear antigen-1 in productive virus cycle.
Nováková Z; Krchnák V; Roubal J
Acta Virol; 1988 Jul; 32(4):349-52. PubMed ID: 2903640
[TBL] [Abstract][Full Text] [Related]
36. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
37. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis.
Masuoka S; Kusunoki N; Takamatsu R; Takahashi H; Tsuchiya K; Kawai S; Nanki T
PLoS One; 2018; 13(12):e0208957. PubMed ID: 30533036
[TBL] [Abstract][Full Text] [Related]
39. [Rheumatoid arthritis associated nuclear antigen (RANA) and Epstein-Barr virus (EBV)].
Li ZG
Zhonghua Yi Xue Za Zhi; 1988 Aug; 68(8):447-9, 32. PubMed ID: 2852534
[No Abstract] [Full Text] [Related]
40. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis.
Alspaugh MA; Henle G; Lennette ET; Henle W
J Clin Invest; 1981 Apr; 67(4):1134-40. PubMed ID: 6259211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
